These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686 [TBL] [Abstract][Full Text] [Related]
3. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Shangary S; Wang S Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the therapeutic perspectives of Nutlin-3. Secchiero P; Bosco R; Celeghini C; Zauli G Curr Pharm Des; 2011; 17(6):569-77. PubMed ID: 21391907 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation. Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807 [TBL] [Abstract][Full Text] [Related]
7. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161 [TBL] [Abstract][Full Text] [Related]
8. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. Duan L; Perez RE; Chen L; Blatter LA; Maki CG J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376 [TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Cheok CF; Dey A; Lane DP Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259 [TBL] [Abstract][Full Text] [Related]
11. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3. Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163 [TBL] [Abstract][Full Text] [Related]
12. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729 [TBL] [Abstract][Full Text] [Related]
13. Nutlins and ionizing radiation in cancer therapy. Impicciatore G; Sancilio S; Miscia S; Di Pietro R Curr Pharm Des; 2010; 16(12):1427-42. PubMed ID: 20166982 [TBL] [Abstract][Full Text] [Related]
14. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction. Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266 [TBL] [Abstract][Full Text] [Related]
15. On p53 revival using system oriented drug dosage design. Haseeb M; Azam S; Bhatti AI; Azam R; Ullah M; Fazal S J Theor Biol; 2017 Feb; 415():53-57. PubMed ID: 27979498 [TBL] [Abstract][Full Text] [Related]
16. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di RorĂ A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044 [TBL] [Abstract][Full Text] [Related]
17. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents. Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344 [TBL] [Abstract][Full Text] [Related]
18. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074 [TBL] [Abstract][Full Text] [Related]